Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes

American Journal of Cardiovascular Drugs

Volumn 12, Issue 2, 2012, Pages 127-135

  El Menyar, Ayman ^a,b   AlHabib, Khalid F ^c   Al Motarreb, Ahmed ^d   Hersi, Ahmad ^c   Al Faleh, Hussam ^c   Asaad, Nidal ^a,b   Al Saif, Shukri ^e   Almahmeed, Wael ^f   Sulaiman, Kadhim ^g   Amin, Haitham ^h   Al Lawati, Jawad ⁱ   Alsheikh Ali, Alawi A ^f,j   AlQahtani, Awad ^a   Al Sagheer, Norah Q ^k   Singh, Rajvir ^a   Al Suwaidi, Jassim ^a,b  

^a HAMAD GENERAL HOSPITAL   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^d Sana's University   (Yemen)

^e Saud Al Babtain Cardiac Hospital   (Saudi Arabia)

^f SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^g ROYAL HOSPITAL   (Oman)

^h Mohammed Bin Khalifa Cardiac Centre   (Bahrain)

ⁱ MINISTRY OF HEALTH   (Oman)

^j TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Al Thawra Hospital   (Yemen)

more..

Author keywords

acute coronary syndrome; antiplatelet agents; aspirin; clopidogrel; revascularization.

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84863361813     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11597580-000000000-00000     Document Type: Article

References (33)

1. Chen WH. Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter? Curr Cardiol Rep 2006; 8: 301-6
2. White HD. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. Am Heart J 2011; 161: 450-461
3. Yusuf S, Zhao F, Mehta SR, et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502 (Pubitemid 32758501)
4. Sabatine MS, Cannon CP, Gibson CM, et al., CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89 (Pubitemid 40397259)
5. Chen ZM, Jiang LX, Chen YP, et al., COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-21
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16 (Pubitemid 46517957)
7. IVandic BT, Sausemuth M, Ibrahim H, et al. Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention. Clin Chem 2009; 55: 1171-6
8. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-6 (Pubitemid 38353000)
9. Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother 2005; 6: 2027-45 (Pubitemid 41600581)
10. Cheng X, Chen WH, Simon DI. Aspirin resistance or variable response or both? Am J Cardiol 2006; 98: 11N-7N
11. Rich JD, Cannon CP, Murphy SA, et al. Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol 2010; 56: 1376-85
12. Alexander JH, Harrington RA, Tuttle RH, et al., PURSUIT Investigators. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Platelet IIb/IIIa in unstable angina: receptor suppression using Integrilin therapy. Am J Cardiol 1999; 83: 1147-51
13. Lancaster GI, Lancaster CJ, Radley D, et al. Prior aspirin use in unstable angina predisposes to higher risk: the aspirin paradox. Int J Cardiol 2001; 80: 201-7 (Pubitemid 32905412)
14. Bhatt DL, Fox KA, Hacke W, et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17
15. Santopinto J, Gurfinkel EP, Torres V, et al. Prior aspirin users with acute non- ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Am Heart J 2001; 141: 566-72 (Pubitemid 32260722)
16. Ambrosio G, Steinhubl S, Gresele P, et al. Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. Eur J Cardiovasc Prev Rehabil 2011; 18 (1): 121-8
17. Spencer FA, Santopinto JJ, Gore JM, et al. Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2002; 90: 1056-61 (Pubitemid 35335593)
18. Borzak S, Cannon CP, Kraft PL, et al., TIMI 7 Investigators. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol 1998; 81: 678-81 (Pubitemid 28146438)
19. Col NF, Yarzbski J, Gore JM, et al. Does aspirin consumption affect the presentation or severity of acute myocardial infarction? Arch Intern Med 1995; 155: 1386-9
20. Garcia-Dorado D, Théroux P, Tornos P, et al. Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. Circulation 1995; 92: 1743-8
21. El-Menyar A, Zubaid M, Rashed W, et al. Comparison of men and women with acute coronary syndrome in six Middle Eastern countries. Am J Cardiol 2009; 104: 1018-22
22. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106: 974-80 (Pubitemid 34925333)
23. Granger CB, Goldberg RJ, Dabbous O, et al., Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345-53 (Pubitemid 37310196)
24. Soiza RL, Leslie SJ. Prior clopidogrel use and outcome of acute coronary syndrome. Int J Cardiol 2006; 111: 313-4 (Pubitemid 44107565)
25. El-MenyarA,ZubaidM, SulaimanK, et al. In-hospitalmajor clinical outcomes in patients with chronic renal insufficiency presenting with acute coronary syndrome: data from a registry of 8176 patients.Mayo Clin Proc 2010; 85: 332-40
26. Al Suwaidi J, Zubaid M, El-Menyar AA, et al. Prevalence of the metabolic syndrome in patients with acute coronary syndrome in six middle eastern countries. J Clin Hypertens (Greenwich) 2010; 12: 890-9
27. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
28. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304
29. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. [published erratum appears in Circulation 2007; 115 (15): e407]. Circulation 2007; 115: 1481-501 (Pubitemid 46648385)
30. Kastrati A, von Beckerath N, Joost A, et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110: 1916-9 (Pubitemid 39331901)
31. EikelboomJW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003; 41: 966-8 (Pubitemid 36315538)
32. Angiolillo DJ. ADP receptor antagonism: what's in the pipeline? Am J Cardiovasc Drugs 2007; 7: 423-32 (Pubitemid 350256050)
33. Neubauer H, Kaiser AF, Endres HG, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance. The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 2011; 9: 3